Publication | Closed Access

The IMPACT Study: Valganciclovir Prophylaxis for until 200 Days Post-Transplant in High Risk Kidney Recipients Substantially Reduces the Incidence of CMV Disease.

TransplantationKidney TransplantKidney TransplantationSolid Organ TransplantationCmv DiseaseClinical EpidemiologyTransplantation MedicineGraft SurvivalValganciclovir ProphylaxisMedicineNephrologyImpact Study